Clinical Trial Update: Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating pembrolizumab with carboplatin and paclitaxel for Stage I triple-negative breast cancer is currently active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• KEYTRUDA (PEMBROLIZUMAB)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: MedSIR | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING